World-renowned experts
toumei imagetoumei image Lectures
Don't miss our highlights coverage of current lectures to get the most recent information available on late-breaking research, and clinical results involving infectious diseases and the use of levofloxacin.

To view the lectures marked MULTIMEDIA, you will require Adobe Flash Player 10 or later. Also, to view QuickTime videos in the lectures, you will require QuickTime Player 4.1 or later. Adobe Flash Player and QuickTime Player are available at and respectively.

dot Optimal Strategic Therapy for Community-Acquired Pneumonia: Levofloxacin at the Forefront of Fluoroquinolone CAP Therapy
(Chaired by Dr. Moh. Arifin Nawas, SpP(K), MARS)

dot New Treatment Strategies for the Eradication of Helicobacter pylori—Combating the Global Trend of Antibiotic Resistance
dot Levofloxacin: a Mainstay of Fluoroquinolone-Based Therapy-After Twenty Years of Use, Levofloxacin Remains Safe and Effective
(Moderated by Kurt G. Naber, MD, PhD)
dot Optimizing the Management of Prostatitis: Levofloxacin and Silodosin—Strategies Aimed at Optimal Treatment for Prostatitis
(Co-Chaired by Kurt G. Naber, MD, PhD and J. Curtis Nickel, MD, FRCSC)
dot Smarter Therapy: Guidelines for Optimal Management of Neutropenic Cancer Patients
(Interview with Professor Thomas M. File, Jr.)
dot Optimal Management of RTI – Intriguing New Results in ABECOPD in Asia
(Interview with Prof. Hans H. Liu, MD, FACP)
dot Tracking Susceptibility and Reducing Resistance - Fluoroquinolones at the Forefront in the Fight Against Bacterial Pathogens
(Interview with Prof. Rafael Cantón, PhD )
dot The Way Forward: High-Dose, Short-Course Levofloxacin Leads the Field
(Interview with Prof. Lala M. Dunbar, MD, PhD )
dot The Role of 750 mg Once-Daily Levofloxacin in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Diseases
(Interview with Prof. Ronald F. Grossman, MD, FRCPC, FCCP, FACP )

dot The Efficacy, Tolerability, and Benefits of 750 mg Once-Daily Levofloxacin in the Treatment of Community-Acquired Pneumonia
(Interview with Prof. Thomas M. File, Jr, MD, MS )
dot Levofloxacin for the Management of Hospital-Acquired, Ventilator-Associated and Healthcare-Associated Pneumonia
(Interview with Prof. Marin H. Kollef)
dot The Use of Levofloxacin for the Treatment of Acute Exacerbation of Chronic Bronchitis
(Interview with Prof. Hartmut Lode)
dot New Insights in the Treatment of Severe Infections in the Multiple-Drug Resistant Situation
(Highlights of the Daiichi Pharmaceutical Co., Ltd. Satellite Symposium to the 11th International Congress on Infectious Diseases)
dot Levofloxacin Stands Above the Rest: A Fluoroquinolone with Both Efficacy and Safety
(Highlights of a Special Roundtable Discussion)
dot Levofloxacin in the Medical Management of Community-acquired Pneumonia
(Interview with Prof. Andy I. M. Hoepelman)
dot New Challenges for Levofloxacin in the Fight Against Infectious Diseases
(Interviews with World-Renowned Experts)
dot New Era for the Treatment of Respiratory Tract infections
(Daiichi Pharmaceutical Co., Ltd., Special Interview)
dot Safety Assessment of Antimicrobial Agents: Criteria for the Balance Between Efficacy and Safety
(Aventis Pharma/Daiichi Pharmaceutical Co. Ltd./
Ortho-McNeil Pharmaceutical Inc. Joint-Sponsored Symposium
At the 22nd International Congress of Chemotherapy)

dot Defining the Appropriate Critical Pathway for the Treatment of Infectious Diseases: Challenging Drug-Resistant Pathogens
(Highlights of a Special Roundtable Discussion)

dot Quinolones Are Not All the Same: Different Safety Profiles for Specific Compounds
(Highlights of a Special Roundtable Discussion)

dot The Role of Levofloxacin for the Treatment of Respiratory Tract Infections
(Highlights of a Special Roundtable Discussion)

toumei image ©1998- BIOMEDIS International, Ltd. All rights reserved. Reproduction in any manner in whole or part prohibited.